What sector does Nephrocare Health Serv L belong to?

Nephrocare Health Serv L operates in the Healthcare sector, specifically the Healthcare Service Provider industry, and is listed on the NSE.

What is the current share price of NEPHROPLUS?

As of the latest available quote, NEPHROPLUS traded at ₹765.35. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of NEPHROPLUS?

Nephrocare Health Serv L has a price-to-earnings (P/E) ratio of about 90.04. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of NEPHROPLUS?

The market capitalisation of Nephrocare Health Serv L is approximately ₹7,696 Cr.

Is Nephrocare Health Serv L profitable?

For its latest reported financial year, Nephrocare Health Serv L recorded a net profit margin of about 7.71%.

Does NEPHROPLUS pay a dividend?

Nephrocare Health Serv L does not currently show a dividend yield in our data.

What is the return on equity (ROE) of NEPHROPLUS?

Nephrocare Health Serv L has a return on equity (ROE) of about 8.83%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of NEPHROPLUS?

Over the past 52 weeks, NEPHROPLUS has traded between a low of ₹446.00 and a high of ₹781.50.

Nephrocare Health Serv L

NEPHROPLUS NSE Healthcare Healthcare Service Provider

₹765.35

+2.42%

Delayed · cached 15 min

Fair value analysis

NEPHROPLUS

Nephrocare Health Serv L

₹747.25

Close used for this calculation

₹321.42Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

47/100

Profitability17/25

Returns3/25

Balance Sheet21/25

Efficiency6/25

Growth9/25

Average

Quality radar

Consensus fair value

₹321.42

Above FV

▼ -57.0% against the close used

Model range ₹84.72 – ₹544.51

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹84.72Fair value₹321.42Bull₹544.51

FairClose

52-week traded range

52W low ₹449.1552W high ₹751.30

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Nephrocare Health Serv L closed at ₹747.25, 132.5% above the consensus fair value of ₹321.42 drawn from 9 valuation models.

Financial DNA score 47/100 — Average. P/E of 90.4x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹217.78

-70.9%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹143.66

-80.8%

√(22.5 × EPS × BVPS)

EPS=7.66, BVPS=119.75 · outside Graham range (P/E 90.4, P/B 6.2) — asset-light, treat as a rough floor

Graham Formula

₹310.83

-58.4%

EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate

g=17.6%, FD=7%

P/E Fair Value

₹322.10

-56.9%

EPS × 42.05x (sector P/E)

EPS=7.66, Sector P/E=42.05x

Peter Lynch (PEG)

₹134.82

-82.0%

EPS × Growth% (PEG = 1 is fair)

EPS=7.66, g=17.6%

EV/EBITDA

₹544.51

-27.1%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=3.16B

Book Value (P/B)

₹84.72

-88.7%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=119.75, ROE=8.8%, g=6%, r=10%

Reverse DCF

₹747.25

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 28.8% | Historical: 17.6%

Margin of Safety

₹186.44

-75.0%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=248.59, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer